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In yeast, the activators of mRNA decapping, Pat1, Lsm1 and Dhh1, accumulate in processing bodies (P bodies) together with other proteins of the
5′-3′-deadenylation-dependent mRNA decay pathway. The Pat1 protein is of particular interest because it functions in the opposing processes of
mRNA translation and mRNA degradation, thus suggesting an important regulatory role. In contrast to other components of this mRNA decay
pathway, the human homolog of the yeast Pat1 protein was unknown. Here we describe the identification of two humanPAT1 genes and show that one
of them, PATL1, codes for an ORF with similar features as the yeast PAT1. As expected for a protein with a fundamental role in translation control,
PATL1 mRNAwas ubiquitously expressed in all human tissues as were the mRNAs of LSM1 and RCK, the human homologs of yeast LSM1 and
DHH1, respectively. Furthermore, fluorescence-tagged PatL1 protein accumulated in distinct foci that correspond to P bodies, as they co-localized
with the P body components Lsm1, Rck/p54 and the decapping enzyme Dcp1. In addition, as for its yeast counterpart, PatL1 expression was required
for P body formation. Taken together, these data emphasize the conservation of important P body components from yeast to human cells.
© 2007 Elsevier B.V. All rights reserved.Keywords: Pat1; Decapping; mRNA turnover; Processing bodies; P bodies1. Introduction
Distinct cytoplasmic foci named processing bodies (P bodies)
have recently emerged as dynamic compartments with key roles
in the regulation of cellular mRNA fates. P bodies are conserved
from yeast to humans and are sites where mRNAs that are not
translated are directed either to the degradation or to storage for
subsequent return to translation [1–5]. Consistent with this role,
translationally inactive mRNAs co-localize in P bodies together
with proteins that function in translation repression, mRNA-⁎ Corresponding author. Departamento Ciencias Experimentales y de la Salud,
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[1–5].
A conserved core of proteins from the mRNA decay ma-
chinery is found in P bodies from yeast to humans, however, it is
important to note that there is an increased complexity in P body
composition and function in higher eukaryotes [2,3,5]. Thus,
human P bodies contain additional proteins that have no yeast
counterparts, for example, factors involved in RNAi such as
GW182 or Argonaute proteins. Moreover, in Saccharomyces
cerevisiae P bodies increased in size and number by exposing
yeast cells to growth limitation, increased cell density or stress
[6] while in humans, P body's size and numbers are increased in
proliferating cells [7].
From the two main eukaryotic pathways of mRNA decay, the
3′-5′-deadenylation-dependent exonucleolytic pathway and the
5′-3′-deadenylation-dependent decapping pathway, only the
proteins required for the latter have yet been shown to localize in
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Dcp2, the 5′-to 3′-exonuclease Xrn1 and proteins that function
as activators of decapping such as the helicase Dhh1, the
heteroheptameric Lsm1–7 ring and Pat1 [8]. The mechanisms
by which these proteins promote decapping are unknown, how-
ever, they directly interact and form a complex [8–11]. Inter-
estingly, under certain conditions such as overexpression and
stress, Dhh1 and Pat1 proteins are also required for repression of
translation [12].
The yeast Pat1 protein has very interesting features. In addi-
tion to its role in translation repression and mRNA degradation
mentioned above, it is also required for translation initiation
[13]. Furthermore, Pat1 is the only decapping activator protein
that, besides interacting with deadenylated mRNAs, also binds
to eIF4G-, eIF4E- and Pab1p-associated polyadenylated mRNA
and locates to polysomes [9,14]. The function of Pat1 in the
antagonistic processes of translation and translation repression/
mRNA degradation suggest a key regulatory role for this pro-
tein. In fact, since the exit of the mRNA from translation to a
non-translation state seems crucial for P body formation and
Pat1 is associated to the mRNA in both states, it has been sug-
gested that Pat1 could act as a seed protein for P body formation
[8].
The 5′-3′-deadenylation-dependent decapping pathway of
mRNA degradation is well conserved from yeast to humans.
With the exception of Pat1, all the corresponding human
homologs have been identified and shown to localize in P bodies
as do their yeast counterparts ([2] and references therein). The
only characterized homolog of Pat1 in higher eukaryotes was
identified in early stage oocytes of Xenopus [15]. The protein,
named p100, locates to the cytoplasm [15] and co-precipitates
with non-adenylated and polyadenylated mRNA [16]. These
similarities to its yeast counterpart suggest that Pat1 function is
conserved in higher eukaryotes. Here we describe the human
homologs of the yeast Pat1 protein and show that one of them,
PatL1, is located in P bodies and required for their formation.
2. Materials and methods
2.1. In silico protein sequence analysis
We retrieved PatL1-related protein sequences and ESTs from the Ensembl
(http://www.ensembl.org) and NCBI (http://www.ncbi.nlm.nih.gov) databases
[17,18] using BLAST-based sequence searches [19] for homologs of S. cerevisiae
Pat1 (YCR077C). The multiple sequence alignment of the identified PatL1
homologs was generated with the program MAFFT [20] (Fig. S3) and the human
PatL1 and PatL2 sequence alignment by CLUSTAL W [21] (Fig. S4). The
alignment figures were prepared and illustrated using the editor Jalview [22]. We
used the online service PSIPRED [23] to predict the secondary structure of PatL1
homologs in five different species (Fig. S3); some divergence of the predicted
structures is expected because of prediction inaccuracies and relatively low
sequence conservation between species.
2.2. Plasmids
cDNA clones corresponding to PATL1 (RZPD: DKFZp451I053) and PATL2
(IMAGE: 5227850) sequences were purchased from Deutsches Ressourcenzen-
trum fuer Genomforschung (http://www.rzpd.de). For the expression of
fluorescence-tagged PatL1 in mammalian cells, the PATL1 ORF was amplified
by PCR with specific primers introducing a 5′-XhoI site followed by a Kozakconsensus site [24] and a 3′-XmaI site that results in a deletion of the stop codon.
The corresponding PCR fragment was then subcloned into pDsRed1-N1,
pDsRed1-C1, pEGFP-N1 and pEGFP-C1 (BD Clontech) by using the XhoI and
XmaI restriction sites. All the primers used for these and constructs described
below are given in the Supplemental materials (Table S2). The GFP-DCP1
plasmid with an EGFP-N1 backbone was previously described [25].
For the generation of 32P-labeled RNA probes, five pGEMT-derived
constructs containing between 400 and 570 nt of the corresponding ORFs were
generated by PCR amplification and subsequent ligation into pGEMT vectors
(Promega). PATL1 and PATL2 sequences were amplified from the above
described cDNA clones, LSM1 and RCK sequences from pYCFPhLSM1 [26]
and pQE30/RCK [27], respectively, and β-actin sequence from human genomic
DNA. All generated constructs were confirmed by DNA sequence analysis.
2.3. Northern and Western blot analysis
The Northern blot membranes containing poly (A)+ RNA from human adult
and fetal tissueswere purchased fromBDClontech. For the generation of (−) strand
32P-labeledRNAprobes, the linearized pGEM-T-derived plasmidswere used for in
vitro transcription with Strip-EZ™ RNA SP6/T7 kit (Ambion). Hybridizations
were performed with ULTRAhyb® Ultrasensitive Hybrization Buffer (Ambion).
Radioactive signals were visualized and quantified using a Molecular Dynamics
Typhoon 8600 Phosphorimager and ImageQuant 5.2 software.
For protein extraction, cells were harvested in ice-cold phosphate-buffered
saline, sonicated and centrifuged (10,000×g for 20 min at 4 °C). Western blots
were performed following standard procedures [28]. The luminescence signals
were visualized and quantified using the FUJIFILM Luminescent image
analyzer LAS-100 and the Image Gauge 3.12 program.
2.4. Antibodies and small interfering RNAs
The following primary antibodies were used: rabbit anti-Lsm1 polyclonal
antibody [26] (1:1000 dilution), rabbit anti-Rck/p54 polyclonal antibody (MBL
International Co.) (1:500 and 1:2000 dilutions for Western and immunofluo-
rescence analysis, respectively) and mouse anti-tubulin monoclonal antibody
(Sigma) (1:1000 dilution). The following secondary antibodies were used:
peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies (Sigma)
(1:1000 dilution) and Alexa568-conjugated goat anti-rabbit antibody (Molecular
Probes) (1:2000 dilution).
Rck/p54 (sense strand: 5′-GGAGGAGAGCAUUCCCAUUTT-3′), PatL1
#1 (sense strand: 5′-CUAGAAGAUCCAGCUAUUATT-3′) and PatL1 #2
(sense strand: 5′-CCAGGAAGUCUGAAUACCATT-3′) siRNA duplexes were
purchased from Ambion. The siControl Non-targeting siRNA #1 (Dharmacon)
was used as a negative control.
2.5. Cell culture, transfection and FACS analysis
HeLa cells were grown as recommended by the American Type Cell Culture
Collection. Transfections were performed on glass slides (Menzel Gläser) after
cells had reached 60% confluency by using LipofectAMIN™2000 (Invitrogen).
Cells were processed 24 to 30 h post-transfection with marker plasmids and 72 h
post-transfection with siRNAs. All siRNAs were transfected at a final
concentration of 50 nM. FACS analysis of 2×104 cells were performed
between wavelengths of 515 to 545 nm in a FACScan (Becton Dickinson) using
CellQuest™ Version Mac AppR 3.0.1.
2.6. Immunofluorescence and co-localization analysis
Immunofluorescence analysis were performed as previously described [26].
The cells were mounted in Vectashield mounting medium with DAPI (Vector
Laboratories, Inc.). Images were visualized using a LeitzAristoplan fluorescence
microscope. The digitized images were taken with a AxioCamColor camera
(Zeiss) and analysed with AxioVision 3.0 programme (Zeiss). The pictures were
then compiled with Adobe Photoshop® 5.0.
Confocal imaging was performed using a Nipkow-disc-based scanning head
(QLC-100, VisiTech international) attached to an upright microscope (Eclipse
600, Nikon) equipped with a 100× oil lens (Plan Apo 1.4, Nikon). The light
Fig. 1. Northern blot analysis of PATL1, LSM1 and RCK mRNAs in various
adult human tissues. A Northern blot with poly(A)+ RNA from adult human
brain (lane 1), heart (lane 2), skeletal muscle (lane 3), colon (lane 4), thymus
(lane 5), spleen (lane 6), kidney (lane 7), liver (lane 8), small intestine (lane 9),
placenta (lane 10), lung (lane 11) and leukocytes (lane 12) was hybridized with
32P-labeled RNA probes corresponding to PATL1, LSM1 and RCK mRNAs.
Isoforms of PATL1 mRNAs are indicated by arrows (a–d). A probe specific for
β-actin was used to control equal loading of poly(A)+ RNA.
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and YCA-series, Melles Griot, respectively). A double-dichroic mirror between
the microlens- and pinhole-disc reflects the emission light in the range between
500 and 550 nm as well as above 580 nm. Background light was eliminated using
appropriate barrier filter. To check for co-localization, images were analyzed
using ImageJ software (Wayne Rasband, National Institute of Mental Health).
3. Results and discussion
3.1. Sequence homology of human PatL1 and PatL2 to yeast Pat1
To identify the human homolog of the S. cerevisiae Pat1
protein, a PSI-BLAST search was performed using the amino
acid sequence of Pat1 as query. Two human ENSEMBL entries
with significant homology were found, indicating the existence
of two different Pat1 homologs in humans. The corresponding
genes ENSG00000166889 and ENSG00000184710 were
named PAT1-like 1 (PATL1) and PAT1-like 2 (PATL2), respec-
tively. PATL1 maps to 11q12.1, consists of at least 18 exons and
encodes one predicted open reading frame (ORF) of 770 amino
acids (Figs. S1, S4). PATL2 maps to 15q21.1 and consists of at
least 15 exons. The comparison of different cDNA sequences
from PATL2 indicates that several alternative splicing events
may take place (Figs. S2, S4).
Based on current gene databases, the existence of two PAT1
homologs is also observed in other vertebrates, while inverte-
brates have only a single PAT1 gene (Table S1).When compiling
a multiple protein sequence alignment of the ENSEMBL se-
quences of PatL1 and PatL2 homologs, including yeast Pat1,
Patr1 from Caenorhaditis elegans and CG5208 from Droso-
phila melanogaster [2] (Fig. S3, Table S1), we found that the
highest level of homology lies within the C-terminal part of
PatL1- and PatL2-related proteins. Interestingly, twelve amino
acids are strictly conserved in all Pat1 homologs, suggesting an
important functional or structural role. The N-terminal part of the
PatL1 protein, conserved in all PatL1 homologs but absent in all
PatL2 ones, is rich in aspartates/glutamates and many prolines.
A glutamine-rich region and frequently occurring short
glutamine-containing sequence motifs (QQ, QxQ and QxxQ)
are also contained in human PatL1 and PatL2, which may play a
functional role in RNA binding.
3.2. The mRNAs of PATL1, RCK and LSM1 are ubiquitously
expressed
In yeast, decapping in the main 5′-3′-deadenylation-depen-
dent pathway of mRNA decay is activated by Pat1, Lsm1–7 and
Dhh1, which interact with each other in an mRNA-independent
manner [9,29–31]. Since this decay pathway is conserved in
human cells and is a major player in the regulation of mRNA
turnover, one would expect that the human homolog of Pat1 as
well as Lsm1 and Dhh1 (named Rck/p54 in humans) are
expressed in all tissues. To test this, we hybridized 32P-labeled
RNA probes derived from the ORFs of human PATL1, PATL2,
LSM1 and RCK genes to poly (A)+ RNA of various adult
human tissues, which was normalized to its β-actin mRNA
content in a Northern blot. A main 4.4-kb transcript of PATL1
was detected in all tissues (Fig. 1). Furthermore, three additionaltranscripts of approximately 7 kb, 3 kb and 2.5 kb were visible
with lower intensity in some tissues. Since the PATL1 gene
consists of at least 18 exons, these isoforms could reflect alter-
native splicing events and/or different sites of polyadenylation.
From the four transcripts, only the 4.4 kb and the 3 kb form are
supported by cloned cDNAs and are the result of the alternative
use of different sites of polyadenylation (Fig. Sl1). In contrast to
PATL1, the analysis of PATL2 expression did not give any
detectable signal (data not shown). Since significantly fewer
ESTs have been found for PATL2 than for PATL1 (more than
200 for PATL1 vs. 20 for PATL2), this would argue that the
transcript level of PATL2 is either very low and/or maybe limited
to some specific tissues as is the case of the Xenopus ortholog
p100 [16].
In addition to PATL1 transcripts, a LSM1 transcript of
approximately 0.95 kb and a RCK transcript of approximately
7.5 kb were detected in all tested tissues (Fig. 1). The transcript
sizes were consistent with previously described data (NCBI
identifier NM_014462 and [32]). Interestingly, the mRNA
Fig. 2. Fluorescence-tagged PatL1 accumulates in cytoplasmic foci. Transfected HeLa cells expressing either the EGFP fused to the C-terminus of PatL1 (PatL1-
EGFP) (A–C), or the RFP fused to the C-terminus of PatL1 (PatL1-dsRed1) (D–F) were grown on slides, fixed 24 h after transfection and counterstained with DAPI.
Fluorescent proteins were then visualized by confocal microscopy. The EGFP fluorescence is shown in green (A), the RFP fluorescence in red (D) and the DAPI
fluorescence in blue (B, E). Merged pictures are shown in the right handed column (C, F). The indicated bars represent 10 μm.
1789N. Scheller et al. / Biochimica et Biophysica Acta 1773 (2007) 1786–1792levels varied in different tissues. For instance, high levels of
LSM1, RCK and PATL1 transcripts were detected in the heart,
whereas the levels in brain tissue were low or moderate (Fig. 1).
Assuming that transcript levels correspond to protein levels, this
may reflect a tissue-specific regulation of mRNA turnover.Fig. 3. Co-localization of PatL1 with Lsm1, Rck/p54 and Dcp1 in processing bodies.
C-terminus of PatL1 (PatL1-EGFP) (A–C) or to the N-terminus of PatL1 (EGFP-PatL
of PatL1 (DsRed1-PatL1) was co-transfected with EGFP-Dcp1(G–I). After transfectio
with anti-Lsm1 antibody (A–C) or anti-Rck/p54 antibody (D–F) and Alexa568-conju
microscopy. The GFP fluorescence is shown in green (A, D, H), the RFP and Alexa5
column (C, F, I). The indicated bars represent 10 μm.3.3. PatL1 accumulates in cytoplasmic foci
The ubiquitous expression of the PATL1 together with the
RCK and LSM1 transcripts makes PatL1 the most likely
candidate for the yeast Pat1 homolog. We therefore focussed onHeLa cells were transfected with plasmids expressing the EGFP-tag fused to the
1) (D–F). In addition, the plasmid expressing the RFP-tag fused to the N-terminus
n, cells were grown for 24 h on slides and fixed. Then, cells were counterstained
gated secondary antibodies. The fluorescence signals were visualized by confocal
68 fluorescences in red (B, E, G). Merged pictures are shown in the right handed
1790 N. Scheller et al. / Biochimica et Biophysica Acta 1773 (2007) 1786–1792this protein in the subsequent studies. To analyze the subcellular
distribution of PatL1, plasmids for exogenous expression in
mammalian cells of fluorescence-tagged PatL1 were generated.
To avoid functional impairment of PatL1 due to its fusion to
fluorescent proteins, the fluorescent tags were introduced either at
the N- or the C-terminus. In addition, two different fluorescent
proteins, the enhanced-green fluorescent protein (EGFP) and theFig. 4. Reduction of PatL1 or Rck/p54 protein levels leads to P body loss. (A). HeLa ce
were grown for 48 and 72 h. Cells were harvested and protein expression was analyzed
100% for non-targeting control siRNA transfection at each time point. (B) HeLa cel
incubated for 48 h and transfected with PatL1-EGFP. Twenty-four hours later, the cell
Fl-1 channel is given on the Y-axis of the graph. (C) HeLa cells transfected either with n
(c, f, i) were grown for 48 h on slides and were either mock transfected (a–f) or transfe
with anti-Lsm1 antibody (a–c), anti-Rck/p54 antibody (d–f) and Alexa568-conjug
visualized by fluorescencemicroscopy. The EGFP fluorescence is shown in green (g–i
The indicated bars represent 10 μm. (D) Percentage of cells displaying P bodies visual
cells per single silencing experiments were counted. Data represent average and S.Dred fluorescent protein (DsRed1)were used.Western blot analysis
of transfected HeLa cells showed that the generated fusion
proteins were expressed with the expected molecular weights
(data not shown). Then the subcellular localization of the
fluorescent proteins was assessed by confocal microscopy in
HeLa cells after 24 to 30 h post-transfection of the corresponding
plasmids. In contrast to the uniform distribution shown by thells transfectedwith eithermock, a non-targeting control siRNAor Rck/p54 siRNA
byWestern blot. The amount of Rck/p54 was normalized to α-tubulin and set to
ls transfected either with non-targeting control siRNA or PatL1 siRNA #1 were
s were analyzed by flow cytometry. The mean fluorescence intensity (MFI) in the
on-targeting control siRNA (a, d, g), Rck/p54 siRNA (b, e, h) or PatL1 siRNA #1
cted with PatL1-EGFP plasmid (g–i). Twenty-four hours later cells were stained
ated secondary antibodies. All cells were counterstained with DAPI (a–i) and
), the Alexa568 fluorescence in red (a–f) and the DAPI fluorescence in blue (a–i).
ized by Lsm1, Rck/p54 or PatL1 after silencing of Rck/p54 or PatL1. At least 100
. of at least two independent experiments.
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fluorescence-tagged PatL1 predominantly localized in the
cytoplasm in small discrete foci (Fig. 2). Moreover, N-terminally
and C-terminally fused PatL1 with either of the fluorescent
proteins showed similar localization patterns (Figs. 2 and 3).
Thus, the accumulation pattern of PatL1 was specific and
independent of the position and the nature of the tag.
3.4. PatL1 co-localizes to Lsm1, Rck/p54 and Dcp1 in P bodies
In yeast, Pat1 localizes to P bodies together with other
proteins from the 5′-3′-deadenylation-dependent mRNA decay
pathway such as Lsm1, Dhh1 and Dcp1, among others [33].
This is also true for all known corresponding human homologs
[25,26,34]. To determine whether the localization of the
fluorescent-tagged PatL1 in cytoplasmic foci corresponds to P
bodies and is not an artefact due to exogenous expression, we
tested the co-localization of PatL1 with the well-characterized P
body components Rck/p54, Lsm1 and Dcp1. HeLa cells were
transfected with a plasmid expressing PatL1 fused to an EGFP
or a DsRed1 fluorescence tag. After 24 h, P bodies were visu-
alized with antibodies directed against endogenous Lsm1 and
Rck/p54, or by co-expression of EGFP-tagged Dcp1 (Fig. 3).
As expected, EGFP-tagged Dcp1, as well as the endogenous
Lsm1 and Rck/p54 accumulated in cytoplasmic foci. Impor-
tantly, the fluorescent PatL1 signal co-localized to the foci
formed by Lsm1, Rck/p54 and Dcp1 fusion protein. This
indicates that PatL1, as yeast Pat1, accumulates in P bodies.
3.5. PatL1 is required for P body formation
In both, yeast and human cells, depletion of certain P body
components influences the size and the number of P bodies. For
example, depletion of proteins acting in early stages of the 5′-
3′-deadenylation-dependent mRNA decay pathway, such as
Dhh1 and its human homolog Rck/p54, leads to a decrease in P
body size and number, indicating that these proteins are
required for P body formation [12,35]. In contrast, depletion
of proteins acting in late stages, such as the exonuclease Xrn1,
has the opposite effect [25,33]. To analyze whether PatL1
influences P body formation, we decreased the level of PatL1 in
HeLa cells by using siRNAs specific for PatL1. Then we
followed the effect of PatL1 depletion on P body formation by
visualizing Lsm1, Rck/p54 and PatL1-EGFP localization in P
bodies (Fig. 4). As a control, we also included in our analysis
siRNAs specific for Rck/p54. Since anti-PatL1-specific anti-
bodies are not available, we followed the silencing activity of
the Pat1L1 siRNAs on the exogenously expressed fluorescent
PatL1 by flow cytometry. Seventy-two hours after siRNA
transfection of Hela cells, protein levels of endogenous Rck/p54
and exogenous PatL1-EGFP were decreased by 80% and 92%,
respectively (Fig. 4A, B). Based on this kinetics of silencing,
cells were transfected either with control siRNA, Rck/p54
siRNA or PatL1 siRNA, grown for 48 h on slides and sub-
sequently mock transfected or transfected with PatL1-EGFP
(Fig. 4C). After additional 24 h in culture, cells were fixed and
stained with anti-Lsm1 or anti-Rck/p54 for immunofluores-cence analysis. PatL1 was detected directly via its fluorescent
EGFP tag. Silencing of Rck/p54 led to a decrease in the number
of P bodies visualized by lack of localization of Rck/p54, Lsm1
and PatL1 in P bodies (Fig. 4C, D). This is consistent with
previously described data that show a requirement of Rck/p54
for P body formation in human cells [35,36]. Interestingly,
silencing of PatL1 also reduced to a large extent the number of P
bodies (Fig. 4C, D) indicating that in human cells PatL1 as
Lsm1 and Rck/p54 are required for P body formation. Similar
results were obtained with a different PatL1-specific siRNA
(data not shown). Thus, human PatL1 parallels yeast Pat1 which
when suppressed also leads to P body loss [12,33].
In summary, PatL1 is, together with Lsm1 and Rck/p54,
ubiquitously expressed in human tissues, localizes to P bodies
and is required for P body formation. These observations
strongly support that PatL1 is a human homolog of the yeast
Pat1. The conservation of Pat1 from yeast to humans suggests an
important role in the regulation of mRNA fates and therefore in
translation control. This regulation is crucial in the coordination
of cell function both under normal and stressed conditions as, for
instance, after virus infections or cell transformation. Indeed, by
using a yeast system it has been recently shown that the P body
components Pat1, Lsm1 andDhh1 are involved in the replication
of positive-strand RNA viruses by influencing translation and
exit from translation to replication of viral RNAs [37–39].
Furthermore, overexpression of Lsm1 and Rck/p54 in human
cells has been associated with tumor development [40–43]. The
identification of such a central player in RNA fate regulation
now opens new options to analyse and manipulate P-body-
dependent processes in humans.
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